Inflammation caused by chronic hepatitis B virus (HBV) infection is associated with the development of cirrhosis and hepatocellular carcinoma; however, the mechanisms by which HBV infection induces inflammation and inflammatory cytokine production remain largely unknown. We analyzed the gene expression patterns of lymphocytes from chronic HBV-infected patients and found that the expression of ZFP36, an AU-rich element (ARE)-binding protein, was dramatically reduced in CD4+ and CD8+ T lymphocytes from chronic HBV patients. ZFP36 expression was also reduced in CD14+ monocytes and in total PBMCs from chronic HBV patients. To investigate the functional consequences of reduced ZFP36 expression, we knocked down ZFP36 in PBMCs from healthy donors using siRNA. siRNA-mediated silencing of ZFP36 resulted in dramatically increased expression of multiple inflammatory cytokines, most of which were also increased in the plasma of chronic HBV patients. Furthermore, we found that IL-8 and RANTES induced ZFP36 downregulation, and this effect was mediated through protein kinase C. Importantly, we found that HBsAg stimulated PBMCs to express IL-8 and RANTES, resulting in decreased ZFP36 expression. Our results suggest that an inflammatory feedback loop involving HBsAg, ZFP36, and inflammatory cytokines may play a critical role in the pathogenesis of chronic HBV and further indicate that ZFP36 may be an important target for anti-inflammatory therapy during chronic HBV infection.
References
[1]
Malik AH, Lee WM (2000) Chronic hepatitis B virus infection: treatment strategies for the next millennium. Annals of internal medicine 132: 723–731.
[2]
Larrubia JR, Benito-Martinez S, Miquel-Plaza J, Sanz-de-Villalobos E, Gonzalez-Mateos F, et al. (2009) Cytokines - their pathogenic and therapeutic role in chronic viral hepatitis. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 101: 343–351.
[3]
Schlaak JF, Tully G, Lohr HF, Gerken G, Meyer zum Buschenfelde KH (1999) HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clinical and experimental immunology 115: 508–514.
[4]
Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, et al. (2006) Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Annals of clinical and laboratory science 36: 144–150.
[5]
Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, et al. (2007) Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. The Journal of experimental medicine 204: 667–680.
[6]
Zou Z, Li B, Xu D, Zhang Z, Zhao JM, et al. (2009) Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. Journal of clinical gastroenterology 43: 182–190.
[7]
Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, et al. (2010) Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS pathogens 6: e1001227.
[8]
Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, et al. (1986) Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proceedings of the National Academy of Sciences of the United States of America 83: 1670–1674.
[9]
Hao S, Baltimore D (2009) The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nature immunology 10: 281–288.
[10]
Khabar KS (2010) Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cellular and molecular life sciences : CMLS 67: 2937–2955.
[11]
Bakheet T, Williams BR, Khabar KS (2006) ARED 3.0: the large and diverse AU-rich transcriptome. Nucleic acids research 34: D111–114.
[12]
Winzen R, Thakur BK, Dittrich-Breiholz O, Shah M, Redich N, et al. (2007) Functional analysis of KSRP interaction with the AU-rich element of interleukin-8 and identification of inflammatory mRNA targets. Molecular and cellular biology 27: 8388–8400.
[13]
Baou M, Norton JD, Murphy JJ (2011) AU-rich RNA binding proteins in hematopoiesis and leukemogenesis. Blood 118: 5732–5740.
[14]
Blackshear PJ (2002) Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochemical Society transactions 30: 945–952.
[15]
Carballo E, Lai WS, Blackshear PJ (1998) Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281: 1001–1005.
[16]
Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, et al. (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Molecular and cellular biology 19: 4311–4323.
[17]
Carballo E, Lai WS, Blackshear PJ (2000) Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95: 1891–1899.
[18]
Ogilvie RL, Sternjohn JR, Rattenbacher B, Vlasova IA, Williams DA, et al. (2009) Tristetraprolin mediates interferon-gamma mRNA decay. The Journal of biological chemistry 284: 11216–11223.
[19]
Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, et al. (2006) Interferons limit inflammatory responses by induction of tristetraprolin. Blood 107: 4790–4797.
[20]
Ogilvie RL, Abelson M, Hau HH, Vlasova I, Blackshear PJ, et al. (2005) Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. Journal of immunology 174: 953–961.
[21]
Stoecklin G, Ming XF, Looser R, Moroni C (2000) Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Molecular and cellular biology 20: 3753–3763.
[22]
Ming XF, Stoecklin G, Lu M, Looser R, Moroni C (2001) Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase. Molecular and cellular biology 21: 5778–5789.
[23]
Sawaoka H, Dixon DA, Oates JA, Boutaud O (2003) Tristetraprolin binds to the 3′-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. The Journal of biological chemistry 278: 13928–13935.
[24]
Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G (2007) Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Molecular biology of the cell 18: 4648–4658.
[25]
Zhao W, Liu M, D'Silva NJ, Kirkwood KL (2011) Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3′ untranslated region. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 31: 629–637.
[26]
Van Tubergen E, Vander Broek R, Lee J, Wolf G, Carey T, et al. (2011) Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer 117: 2677–2689.
[27]
Balakathiresan NS, Bhattacharyya S, Gutti U, Long RP, Jozwik C, et al. (2009) Tristetraprolin regulates IL-8 mRNA stability in cystic fibrosis lung epithelial cells. American journal of physiology Lung cellular and molecular physiology 296: L1012–1018.
[28]
Stoecklin G, Tenenbaum SA, Mayo T, Chittur SV, George AD, et al. (2008) Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. The Journal of biological chemistry 283: 11689–11699.
[29]
Tudor C, Marchese FP, Hitti E, Aubareda A, Rawlinson L, et al. (2009) The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages. FEBS letters 583: 1933–1938.
[30]
Jalonen U, Nieminen R, Vuolteenaho K, Kankaanranta H, Moilanen E (2006) Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages. Mediators of inflammation 2006: 40691. 40691.
[31]
Datta S, Biswas R, Novotny M, Pavicic PG Jr, Herjan T, et al. (2008) Tristetraprolin regulates CXCL1 (KC) mRNA stability. Journal of immunology 180: 2545–2552.
[32]
Barreau C, Paillard L, Osborne HB (2005) AU-rich elements and associated factors: are there unifying principles? Nucleic acids research 33: 7138–7150.
[33]
Cao H, Tuttle JS, Blackshear PJ (2004) Immunological characterization of tristetraprolin as a low abundance, inducible, stable cytosolic protein. The Journal of biological chemistry 279: 21489–21499.
[34]
Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, et al. (1996) A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4: 445–454.
[35]
Carballo E, Gilkeson GS, Blackshear PJ (1997) Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (？/？) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. The Journal of clinical investigation 100: 986–995.
[36]
King EM, Kaur M, Gong W, Rider CF, Holden NS, et al. (2009) Regulation of tristetraprolin expression by interleukin-1 beta and dexamethasone in human pulmonary epithelial cells: roles for nuclear factor-kappa B and p38 mitogen-activated protein kinase. The Journal of pharmacology and experimental therapeutics 330: 575–585.
[37]
Hayashi F, Means TK, Luster AD (2003) Toll-like receptors stimulate human neutrophil function. Blood 102: 2660–2669.
[38]
Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. Journal of leukocyte biology 80: 1197–1213.
[39]
Kaplan IM, Morisot S, Heiser D, Cheng WC, Kim MJ, et al. (2011) Deletion of tristetraprolin caused spontaneous reactive granulopoiesis by a non-cell-autonomous mechanism without disturbing long-term hematopoietic stem cell quiescence. Journal of immunology 186: 2826–2834.
[40]
Kohidai L, Csaba G (1998) Chemotaxis and chemotactic selection induced with cytokines (IL-8, RANTES and TNF-alpha) in the unicellular Tetrahymena pyriformis. Cytokine 10: 481–486.
[41]
Ganem D, Prince AM (2004) Hepatitis B virus infection–natural history and clinical consequences. The New England journal of medicine 350: 1118–1129.
[42]
Yu Y, Gong R, Mu Y, Chen Y, Zhu C, et al. (2011) Hepatitis B Virus Induces a Novel Inflammation Network Involving Three Inflammatory Factors, IL-29, IL-8, and Cyclooxygenase-2. Journal of immunology 187: 4844–4860.
[43]
Mahe Y, Mukaida N, Kuno K, Akiyama M, Ikeda N, et al. (1991) Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements. The Journal of biological chemistry 266: 13759–13763.
[44]
Cougot D, Wu Y, Cairo S, Caramel J, Renard CA, et al. (2007) The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. The Journal of biological chemistry 282: 4277–4287.
[45]
Wang JY, Wang XL, Liu P (1999) Detection of serum TNF-alpha,IFN-beta,IL-6 and IL-8 in patients with hepatitis B. World journal of gastroenterology : WJG 5: 38–40.
[46]
Guidotti LG, Chisari FV (2006) Immunobiology and pathogenesis of viral hepatitis. Annual review of pathology 1: 23–61.
[47]
Wherry EJ (2011) T cell exhaustion. Nature immunology 12: 492–499.
[48]
Liang J, Lei T, Song Y, Yanes N, Qi Y, et al. (2009) RNA-destabilizing factor tristetraprolin negatively regulates NF-kappaB signaling. J Biol Chem 284: 29383–29390.
[49]
Atasoy U, Curry SL, Lopez de Silanes I, Shyu AB, Casolaro V, et al. (2003) Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR. J Immunol 171: 4369–4378.
[50]
Yarovinsky TO, Butler NS, Monick MM, Hunninghake GW (2006) Early exposure to IL-4 stabilizes IL-4 mRNA in CD4+ T cells via RNA-binding protein HuR. J Immunol 177: 4426–4435.
[51]
Casolaro V, Fang X, Tancowny B, Fan J, Wu F, et al. (2008) Posttranscriptional regulation of IL-13 in T cells: role of the RNA-binding protein HuR. J Allergy Clin Immunol 121: 853–859 e854.
